Beginner
- Dose
- 5mg/dia SC Original in PT-BR
- Frequency
- Diário por 10 dias Original in PT-BR
- Duration
- 10 dias / repetir 6 meses Original in PT-BR
- Notes
- Ciclo curto para avaliar resposta Original in PT-BR
KNOWLEDGE · COMPOUNDS
Evidence gap. There is in vitro evidence with cartilage endpoints — two of the references above measure chondrogenic markers and chondrocyte senescence. What does not exist is clinical evidence: a PubMed search restricted to clinical and observational publication types returns one record, and it is Epitalon in retinitis pigmentosa — a different peptide and a different indication. No trial, no patient outcome, no measurement of joint pain, cartilage thickness or function in people. All five references share authors from the St. Petersburg Institute of Bioregulation and Gerontology, the institute associated with the peptide's development; N. S. Linkova is a co-author of all five. No independent replication was found. Search performed →
O Cartalax é um tripeptídeo sintético (Ala-Glu-Asp) desenvolvido pelo Instituto de Biorregulação e Gerontologia de São Petersburgo, sob direção do Prof. Khavinson. É específico para cartilagem articular, estimulando a síntese de proteoglicanos e colágeno tipo II na matriz extracelular cartilaginosa. Faz parte da classe de biorreguladores peptídicos russos, com dados publicados predominantemente em revistas russas. Original in PT-BR
Cartalax is catalogued under Longevity. 0 Eagle articles in this library reference this compound.
Tripeptídeo condroprotetor — estimula síntese de matriz cartilaginosa Original in PT-BR
O Cartalax atua como biorregulador peptídico específico para condrócitos. Sua sequência tripeptídica (Ala-Glu-Asp) tem afinidade por receptores em células da cartilagem, estimulando: (1) Síntese de proteoglicanos (agrecano) — componente principal da matriz cartilaginosa que proporciona resistência à compressão. (2) Síntese de colágeno tipo II — proteína estrutural da cartilagem hialina. (3) Proliferação controlada de condrócitos. O mecanismo segue o modelo de biorregulação peptídica de Khavinson, onde pequenos peptídeos interagem com sequências específicas do DNA para modular a expressão gênica. Original in PT-BR
No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.
Primary literature located on PubMed and checked one by one. Only entries with a PMID and a DOI were accepted; no commercial page was used as evidence. Design, model and limitations are stated for each, because «it has three references» says more than the references do.
The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging
Peptides prevent the forming of secretory phenotype of chondrocytes associated with the aging
Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging
Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides
Evidence gap. There is in vitro evidence with cartilage endpoints — two of the references above measure chondrogenic markers and chondrocyte senescence. What does not exist is clinical evidence: a PubMed search restricted to clinical and observational publication types returns one record, and it is Epitalon in retinitis pigmentosa — a different peptide and a different indication. No trial, no patient outcome, no measurement of joint pain, cartilage thickness or function in people. All five references share authors from the St. Petersburg Institute of Bioregulation and Gerontology, the institute associated with the peptide's development; N. S. Linkova is a co-author of all five. No independent replication was found.
Search performed — ("alanyl glutamyl aspartic acid"[All Fields] OR "Ala-Glu-Asp"[All Fields] OR Cartalax[All Fields] OR "AED peptide"[All Fields]) AND ("clinical trial"[Publication Type] OR "randomized controlled trial"[Publication Type] OR "controlled clinical trial"[Publication Type] OR "observational study"[Publication Type] OR "clinical study"[Publication Type] OR "multicenter study"[Publication Type]) · PubMed · returned: 1 · relevant: 0 · checked 2026-08
Screened out: 12195242 — Epitalon (AEDG, a tetrapeptide) in retinitis pigmentosa — a different peptide and a different indication.
Broad control search — ("Ala-Glu-Asp"[All Fields] OR Cartalax[All Fields] OR "AED peptide"[All Fields]) AND (cartilage[All Fields] OR chondro*[All Fields] OR osteoarthritis[All Fields] OR aggrecan[All Fields] OR SOX9[All Fields] OR COMP[All Fields] OR "type II collagen"[All Fields] OR joint[All Fields]) · PubMed · returned: 2 · checked 2026-08. Both results are already recorded above as verified references; the broad search adds nothing that is missing from this page.
25/ 100
Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.
No research references recorded in the source.
Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for Cartalax.
The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.
Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.
Vial sizes: 20mg — Peptide Calculator
These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.
BPC-157 (reparo tecidual geral) + Cartalax (específico cartilagem) = cobertura articular completa Original in PT-BR
TB-500 atua em tecido conjuntivo amplo. Cartalax é específico para cartilagem. Complementares Original in PT-BR
GHK-Cu estimula colágeno. Cartalax estimula proteoglicanos. Complementares Original in PT-BR
No Eagle article in this library references this compound yet.